Article Text

Download PDFPDF
S21 RECEIVER trial interim analysis: reduction in COPD admissions with digitally supported self-management
  1. A Taylor1,
  2. D Lowe1,
  3. J Anderson1,
  4. G McDowell1,
  5. S Burns2,
  6. P McGinness2,
  7. C Carlin1
  1. 1NHS Greater Glasgow and Clyde, Glasgow, UK
  2. 2Storm ID, Edinburgh, UK


Background The Remote-management of COPD: Evaluating Implementation of Digital Innovations to Enable Routine Care (RECEIVER, NCT04240353) observational cohort trial commenced September 2019. Clinician-patient co-designed progressive web application captures patient-reported outcomes (PROs), Fitbit and home NIV data, and provides self-management resources including asynchronous messaging. Cloud-based clinician dashboard integrates these with clinical summary and event data. Inclusion criteria are diagnosis of COPD with recent severe exacerbation and/or chronic hypercapnia, and daily access to smartphone, tablet or computer. Primary endpoint is patient use of the application. Secondary endpoints include impact on clinical outcomes and deriving AI-based risk predictive models.

Methods We performed a planned interim effectiveness analysis of recruitment, patient-app utilisation and clinical outcomes at week 40, reflecting a minimum of 3 months follow up per patient.

Results 283 patients were screened with 83 patients (average age 65 years) enrolled in RECEIVER by March 2020. Recruitment was paused then due to COVID-19 pandemic. 25/83 patients had home NIV or CPAP. Of the 143 excluded patients, 41 had no access to technology (average age 71 yrs), 42 had not had a recent exacerbation (average age 67 yrs) and 23 declined to participate (average age 67 yrs).

An average of 4.6/patient/week daily PROs were completed, with usage sustained through to week 40. Improvement in patient outcomes versus their preceding year, with reduction in annualised admissions, occupied bed days and community reviews is noted (figure 1). Improved event ratios are maintained in subgroup analyses of home NIV patients, and if follow up is censored at UK COVID-19 lockdown.

Abstract S21 Figure 1

Interim analysis of RECEIVER trial outcome dataReduction in total and average per patient indexed annualised admissions, occupied bed days and community respiratory reviews following RECEIVER trial enrolment

Conclusion Interim analyses of the RECEIVER trial are encouraging, with sustained patient use of the application, and associated positive impact on patient outcomes. Older age of patients lacking access to digital technology is notable. To support post COVID-19 NHS recovery we have scaled-up the digital self-management service, offering this to all COPD patients in NHS GG&C. RECEIVER trial dataset will be combined with large NHS GG&C SafeHaven historical cohort and the scale-up patient data for machine-learning analyses. We aim to train, validate and operationalise prediction models for 12-month mortality, 3-month re-admission and 72-hour exacerbation risk.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.